Waystar Considers Sale Amid Software Sector Challenges

Healthcare software provider Waystar is reportedly exploring strategic options, including a potential sale, according to sources familiar with the matter. The Lehi, Utah, and Louisville, Kentucky-based company has engaged investment bank Evercore to assist in evaluating these options. This comes just two years after Waystar went public on the New York Stock Exchange.

Waystar's Market Challenges

Waystar, known for its technology that automates administrative tasks for hospitals and doctors, has seen its market value decline significantly. The company's stock has fallen by 24% this year, bringing its market capitalization to approximately $4.8 billion. This decline is part of a broader trend affecting the software sector, as investor sentiment shifts amidst concerns over the impact of artificial intelligence on traditional software models.

The company was initially well-received by investors, with its share price climbing from $20 at its IPO to a peak of $45 in 2025. However, recent market pressures have dampened investor enthusiasm. Analysts from Morgan Stanley highlighted in a July report that apprehensions regarding AI advancements potentially disrupting the sector have contributed to this trend.

Strategic Moves and Potential Sale

Waystar's decision to explore a sale reflects its strategic positioning as a technology company, rather than a service provider dependent on manual labor. This positioning was intended to capture the higher valuations typically associated with tech firms. However, with the current market downturn, the company is reassessing its trajectory.

The auction process, facilitated by Evercore, may test the waters to see if investor interest in software businesses is reviving. While sources note that plans are in preliminary stages and a sale is not guaranteed, the exploration of such options highlights the challenges faced by publicly traded software companies in the current economic climate.

Ownership and Historical Context

Waystar was formed in 2017 through the merger of healthcare revenue management firms Zirmed and Navicure. It went public in 2024 with backing from private equity firm EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%, according to data from the London Stock Exchange Group (LSEG).

Neither Waystar nor its major investors, including EQT and CPPIB, have commented on the potential sale. Evercore, the advisory bank for the process, has also not issued a statement.